uniQure (NASDAQ:QURE) CFO Sells $825,000.00 in Stock

Key Points

• uniQure CFO Christian Klemt sold 15,000 shares for $825,000, reducing his holdings by 6.45% to approximately 217,730 shares.
• The stock price for uniQure increased by 3.2% to $54.31, with a market capitalization of $2.98 billion.
• Investment firms are optimistic, with Mizuho raising its price target on uniQure from $30 to $60 and multiple firms rating the stock as "outperform".

uniQure N.V. (NASDAQ:QURE - Get Free Report) CFO Christian Klemt sold 15,000 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christian Klemt also recently made the following trade(s):

• On Wednesday, September 24th, Christian Klemt sold 3,000 shares of uniQure stock. The stock was sold at an average price of $40.04, for a total transaction of $120,120.00.

uniQure Stock Up 3.2%

QURE traded up $1.66 during trading on Friday, hitting $54.31. 11,290,994 shares of the company's stock traded hands, compared to its average volume of 5,557,321. The company's 50 day simple moving average is $17.44 and its two-hundred day simple moving average is $14.89. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure N.V. has a 12-month low of $4.45 and a 12-month high of $55.11. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -13.85 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Sanders Morris Harris LLC raised its stake in shares of uniQure by 12.5% during the 1st quarter. Sanders Morris Harris LLC now owns 114,887 shares of the biotechnology company's stock worth $1,139,000 after acquiring an additional 12,783 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock valued at $3,550,000 after acquiring an additional 261,323 shares in the last quarter. Mraz Amerine & Associates Inc. purchased a new position in uniQure in the first quarter worth $106,000. Diamond Hill Capital Management Inc. increased its position in shares of uniQure by 22.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company's stock worth $876,000 after purchasing an additional 15,333 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 20,720 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on QURE. Mizuho increased their price objective on shares of uniQure from $30.00 to $60.00 and gave the company an "outperform" rating in a report on Thursday. Cantor Fitzgerald raised their target price on shares of uniQure from $47.00 to $80.00 and gave the stock an "overweight" rating in a report on Thursday. Royal Bank Of Canada restated an "outperform" rating on shares of uniQure in a report on Wednesday. Leerink Partners raised their target price on shares of uniQure from $48.00 to $68.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $67.17.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.